[With the soaring sales of weight-loss drugs, Danish pharmaceutical giant Novo Nordisk raised its profit forecast] Novo Nordisk again raised its sales and profit prospects because of the surge in demand for its popular obesity drug Wegovy and diabetes treatment drug Ozenpic. The company stated on Friday that the Danish pharmaceutical company currently expects sales to increase by 32% to 38% this year, higher than the previous 33%.